| name | icsm-offer-tt-after-rp-favorable-pathology-undetectable-psa |
| description | This skill guides clinicians to consider testosterone therapy in postoperative radical prostatectomy patients who have undetectable PSA and favorable pathology (negative margins, seminal vesicles, and lymph nodes). Trigger when a postoperative patient reports recovered undetectable PSA and pathology is clear, raising the question of initiating testosterone replacement. |
Offer testosterone therapy after radical prostatectomy with favorable pathology and undetectable PSA
STEP 1 — Gather Information
Collect postoperative pathology report (margins, seminal vesicles, lymph nodes status), postoperative PSA level (undetectable per assay), symptoms of hypogonadism (e.g., low libido, fatigue, decreased morning erections), and confirm low total testosterone (<12 nmol/L or <300 ng/dL) on two morning fasting measurements.
STEP 2 — Rule In / Rule Out
If pathology shows negative margins, negative seminal vesicles, negative lymph nodes AND PSA is undetectable AND patient is symptomatic with confirmed low testosterone → proceed to evaluate for testosterone therapy. If any margin, seminal vesicle, or lymph node involvement OR PSA is detectable → do not offer testosterone therapy; pursue further oncologic evaluation.
STEP 3 — Classify or Stratify
Classify hypogonadism presence: symptomatic with total testosterone <12 nmol/L (<300 ng/dL) on two occasions → proceed to shared decision‑making. If asymptomatic or testosterone above threshold → testosterone therapy not indicated.
STEP 4 — Decide
If hypogonadism confirmed and postoperative criteria met, engage in shared decision‑making about testosterone therapy formulation (e.g., transdermal gel, intramuscular injection), initiate treatment, and schedule monitoring of PSA and DRE at 3 and 6 months, hematocrit, and testosterone levels per guideline.
Clinical Guardrails / Mimics / Pitfalls
Do not offer testosterone therapy if PSA is detectable, if any pathologic adverse feature (positive margin, seminal vesicle invasion, lymph node positivity), if metastatic or high‑risk disease is suspected, if the patient desires fertility (testosterone therapy is contraindicated), or if there is untreated prostate cancer. Avoid monotherapy for erectile dysfunction without confirmed hypogonadism. Monitor for polycythemia (hematocrit ≥54%) and cardiovascular risk.
Concrete Clinical Example
A 62‑year‑old man underwent robotic radical prostatectomy for Gleason 3+4 prostate cancer. Pathology: negative margins, negative seminal vesicles, negative lymph nodes. One‑month postoperative PSA is <0.01 ng/mL. He reports fatigue, low libido, and decreased morning erections. Morning total testosterone is 8 nmol/L on two checks. After discussing risks and benefits, transdermal testosterone gel is initiated with PSA and DRE checks at 3 and 6 months, hematocrit, and testosterone levels.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036
